相似文献
1
IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.
J Cyst Fibros. 2016 May;15(3):372-9. doi: 10.1016/j.jcf.2015.10.006. Epub 2015 Oct 23.
2
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29.
3
Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.
J Cyst Fibros. 2016 Nov;15(6):783-790. doi: 10.1016/j.jcf.2016.04.005. Epub 2016 Apr 29.
4
Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.
J Cyst Fibros. 2015 Nov;14(6):763-9. doi: 10.1016/j.jcf.2015.02.007. Epub 2015 Mar 6.
5
Predictors of pulmonary exacerbation treatment in cystic fibrosis.
J Cyst Fibros. 2020 May;19(3):407-414. doi: 10.1016/j.jcf.2019.06.008. Epub 2019 Jun 27.
6
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
J Cyst Fibros. 2017 Sep;16(5):600-606. doi: 10.1016/j.jcf.2017.04.003. Epub 2017 Apr 29.
7
Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States.
Curr Med Res Opin. 2017 Apr;33(4):667-674. doi: 10.1080/03007995.2016.1277196. Epub 2017 Feb 9.
8
Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
Ann Am Thorac Soc. 2024 Apr;21(4):595-603. doi: 10.1513/AnnalsATS.202306-576OC.
9
The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations.
J Cyst Fibros. 2019 Nov;18(6):851-856. doi: 10.1016/j.jcf.2019.05.012. Epub 2019 May 28.
10
The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
J Cyst Fibros. 2021 Nov;20(6):932-936. doi: 10.1016/j.jcf.2021.02.012. Epub 2021 Mar 5.
引用本文的文献
1
Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis.
Pediatr Pulmonol. 2025 Mar;60(3):e71019. doi: 10.1002/ppul.71019.
2
Diagnosis and Management of Cystic Fibrosis Exacerbations.
Semin Respir Crit Care Med. 2023 Apr;44(2):225-241. doi: 10.1055/s-0042-1760250. Epub 2023 Feb 6.
3
The association of fecal calprotectin and respiratory exacerbation in cystic fibrosis patients.
BMC Gastroenterol. 2022 Nov 28;22(1):494. doi: 10.1186/s12876-022-02553-x.
4
Antipseudomonal treatment decisions during CF exacerbation management.
J Cyst Fibros. 2022 Sep;21(5):753-758. doi: 10.1016/j.jcf.2022.04.006. Epub 2022 Apr 22.
5
A new path for CF clinical trials through the use of historical controls.
J Cyst Fibros. 2022 Mar;21(2):293-299. doi: 10.1016/j.jcf.2021.11.007. Epub 2021 Dec 5.
6
A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.
Am J Respir Crit Care Med. 2021 Dec 1;204(11):1295-1305. doi: 10.1164/rccm.202102-0461OC.
7
Susceptibility Patterns and Associated Clinical Outcomes in People with Cystic Fibrosis following Approval of Aztreonam Lysine for Inhalation.
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.02327-20.
8
Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.
J Cyst Fibros. 2021 Mar;20(2):257-263. doi: 10.1016/j.jcf.2020.05.008. Epub 2020 Jun 4.
9
Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.
Am J Respir Crit Care Med. 2020 May 15;201(10):1193-1208. doi: 10.1164/rccm.201910-1943SO.
10
The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations.
J Cyst Fibros. 2019 Nov;18(6):851-856. doi: 10.1016/j.jcf.2019.05.012. Epub 2019 May 28.
本文引用的文献
1
Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.
Clin Investig (Lond). 2012;2(2):163-175. doi: 10.4155/cli.11.174.
2
Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.
J Cyst Fibros. 2015 Nov;14(6):763-9. doi: 10.1016/j.jcf.2015.02.007. Epub 2015 Mar 6.
3
Ozone is associated with an increased risk of respiratory exacerbations in patients with cystic fibrosis.
Chest. 2013 Oct;144(4):1186-1192. doi: 10.1378/chest.12-2414.
4
Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age.
Thorax. 2013 Jul;68(7):643-51. doi: 10.1136/thoraxjnl-2012-202342. Epub 2013 Jan 23.
5
Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995-2005.
J Cyst Fibros. 2013 Jul;12(4):332-7. doi: 10.1016/j.jcf.2012.11.011. Epub 2012 Dec 28.
6
Impact of air pollution on cystic fibrosis pulmonary exacerbations: a case-crossover analysis.
Chest. 2013 Apr;143(4):946-954. doi: 10.1378/chest.12-1005.
7
Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations.
Eur Respir J. 2012 Dec;40(6):1324-43. doi: 10.1183/09031936.00080312. Epub 2012 Jun 27.
8
Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis.
Chron Respir Dis. 2012 Feb;9(1):9-16. doi: 10.1177/1479972311433575.
9
Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.
J Cyst Fibros. 2011 Dec;10(6):453-9. doi: 10.1016/j.jcf.2011.07.003. Epub 2011 Jul 30.
10
Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.
Thorax. 2011 Aug;66(8):680-5. doi: 10.1136/thx.2011.161117. Epub 2011 Jun 15.
Zotero 插件